PC
ACOR

PointState Capital’s Acorda Therapeutics ACOR Stock Holding History

PointState Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,500
Closed -$10.1M – 144
2014
Q2 		$10.1M Sell
2,500
-1,667
-40% -$6.8M 0.13% 78
2014
Q1 		$19M Buy
+4,167
New +$16.8M 0.3% 57

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PointState Capital's ACOR Position: Q3 2014 in Review

PointState Capital sold out of Acorda Therapeutics (ACOR) in Q3 2014, closing a stake of 2,500 shares — an estimated $10.1M sold.

PointState Capital first reported a position in ACOR in Q1 2014 and held it in 2 quarters. The position peaked at $19M in Q1 2014. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2014.

  • PointState Capital reported no remaining Acorda Therapeutics position as of Q3 2014 after selling out during the quarter.
  • PointState Capital sold 2,500 Acorda Therapeutics shares in Q3 2014, an estimated $10.1M.
  • PointState Capital first reported a position in Acorda Therapeutics in Q1 2014 and held it in 2 quarters.
  • PointState Capital's Acorda Therapeutics position peaked at $19M in Q1 2014.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2014.

Based on PointState Capital's 13F filing for Q3 2014, filed 14 Nov 2014.